The vast majority (140/144) of protocol-eligible patients had evaluable liquid assay results including 121 cohort A patients (those with newly diagnosed metastatic disease or progressive disease on any-line non-EGFR-targeted therapy) and 19 cohort B patients (those with progressive disease on EGFR-targeted therapy). The gene discussed is EGFR; the disease is metastatic neoplasm.